DK0751709T3 - Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme - Google Patents

Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme

Info

Publication number
DK0751709T3
DK0751709T3 DK94919263T DK94919263T DK0751709T3 DK 0751709 T3 DK0751709 T3 DK 0751709T3 DK 94919263 T DK94919263 T DK 94919263T DK 94919263 T DK94919263 T DK 94919263T DK 0751709 T3 DK0751709 T3 DK 0751709T3
Authority
DK
Denmark
Prior art keywords
bcl
drugs
diseases
prevention
manufacture
Prior art date
Application number
DK94919263T
Other languages
Danish (da)
English (en)
Inventor
John C Reed
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22070248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0751709(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of DK0751709T3 publication Critical patent/DK0751709T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
DK94919263T 1993-05-26 1994-05-26 Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme DK0751709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/066,556 US5550019A (en) 1993-05-26 1993-05-26 Methods of identifying compounds which alter apoptosis
PCT/US1994/005980 WO1994027426A1 (fr) 1993-05-26 1994-05-26 Procedes d'utilisation de bcl-2 pour le traitement therapeutique et la prevention de maladies

Publications (1)

Publication Number Publication Date
DK0751709T3 true DK0751709T3 (da) 2002-03-04

Family

ID=22070248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94919263T DK0751709T3 (da) 1993-05-26 1994-05-26 Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme

Country Status (10)

Country Link
US (4) US5550019A (fr)
EP (2) EP0751709B2 (fr)
JP (2) JP3704348B2 (fr)
AT (1) ATE204704T1 (fr)
CA (1) CA2163439C (fr)
DE (1) DE69428130T3 (fr)
DK (1) DK0751709T3 (fr)
ES (1) ES2160124T3 (fr)
PT (1) PT751709E (fr)
WO (1) WO1994027426A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5539085A (en) * 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US6231852B1 (en) 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2739561B1 (fr) * 1995-10-06 1997-12-26 Inst Nat Sante Rech Med Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere
CA2295500A1 (fr) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Procedes de regulation de la croissance axonale
US6558900B2 (en) * 1996-07-12 2003-05-06 Emory University Regulation of apoptosis and in vitro model for studies thereof
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
CA2285709A1 (fr) 1997-04-01 1998-10-08 The General Hospital Corporation Marqueur moleculaire pour cellules souches musculaires
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
WO2000002578A1 (fr) * 1998-07-10 2000-01-20 Meiji Milk Products Co., Ltd. Remedes contre les maladies liees a l'apoptose
AU5789500A (en) * 1999-07-09 2001-01-30 Burnham Institute, The A method for determining the prognosis of cancer patients by measuring levels ofbag expression
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20010053769A1 (en) 2000-01-21 2001-12-20 Christiane Ferran Use of pro-apoptotic factors in treatment of atherosclerosis
US6773894B1 (en) * 2000-01-21 2004-08-10 Biochain Institute, Inc. Isolation and extraction of subcellularly compartmentalized protein
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7419825B2 (en) * 2001-04-20 2008-09-02 Children's Hospital Of Orange County Isolation of neural stem cells using gangliosides and other surface markers
DE10228187A1 (de) * 2002-06-24 2004-01-22 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Testsystem zum Nachweis von Krebserkrankungen
US8017323B2 (en) * 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
WO2005014017A1 (fr) * 2003-08-08 2005-02-17 Yuji Shino Composition medicinale pour traiter le cancer
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
PL2540820T3 (pl) * 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
US20090069223A1 (en) * 2007-08-21 2009-03-12 Childs Ed W Method for treatment of vascular hyperpermeability
US20100189802A1 (en) * 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
US8192420B2 (en) 2007-12-20 2012-06-05 Acclarent, Inc. Iontophoresis methods
WO2009122580A1 (fr) * 2008-04-03 2009-10-08 株式会社ツムラ Procédé d'analyse biologique de yokukansan
EP2271325A4 (fr) 2008-04-11 2011-11-09 Cytotech Labs Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
US20110059191A1 (en) * 2008-05-23 2011-03-10 Nishihara Co., Ltd. Bcl-2 protein expressing agent, apoptosis inhibiting agent and agent for preventing ultraviolet dna damage of epidermal cell
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
DK2736467T3 (en) 2011-07-25 2018-06-25 Tusker Medical Inc PERSONALIZABLE SYSTEM FOR ANTIFICATION OF THE DRUM MAGNET
WO2015115892A1 (fr) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Moyens et procédés de production d'anticorps stables
US10016304B2 (en) 2015-07-16 2018-07-10 Tusker Medical, Inc. Earplug assembly for iontophoresis system
WO2020219504A1 (fr) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulation de la survie de cellules thérapeutiques et procédés, cellules et acides nucléiques associés à celles-ci
CA3228635A1 (fr) * 2021-08-11 2023-02-16 The Trustees Of The University Of Pennsylvania Modulation de bcl-2 pour ameliorer l'efficacite d'immunotherapie anticancereuse par le recepteur antigenique chimerique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5149628A (en) * 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5328844A (en) 1990-05-09 1994-07-12 University Of Colorado Foundation, Inc. Culture media for mammalian cells
WO1992022640A1 (fr) * 1991-06-10 1992-12-23 Research Development Foundation Cellules de retinoblastome transferees et methode de transfert
EP0633934A1 (fr) * 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Cellules modifiees et procede de traitement

Also Published As

Publication number Publication date
US20080102060A1 (en) 2008-05-01
CA2163439A1 (fr) 1994-12-08
US20030069201A1 (en) 2003-04-10
US6514761B1 (en) 2003-02-04
PT751709E (pt) 2001-12-28
EP0751709A1 (fr) 1997-01-08
DE69428130D1 (de) 2001-10-04
DE69428130T3 (de) 2006-10-12
JP3704348B2 (ja) 2005-10-12
JP3867033B2 (ja) 2007-01-10
EP0751709B1 (fr) 2001-08-29
EP0751709A4 (fr) 1997-09-24
CA2163439C (fr) 2011-01-04
JPH09502083A (ja) 1997-03-04
US5550019A (en) 1996-08-27
EP0751709B2 (fr) 2006-03-29
EP1130087A2 (fr) 2001-09-05
JP2003176236A (ja) 2003-06-24
DE69428130T2 (de) 2002-05-02
US7910370B2 (en) 2011-03-22
WO1994027426A1 (fr) 1994-12-08
EP1130087A3 (fr) 2003-10-29
ES2160124T3 (es) 2001-11-01
US7427495B2 (en) 2008-09-23
ATE204704T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
DK0751709T3 (da) Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme
DK0517820T3 (da) Anvendelse af 3-guanidinopropionsyre ved fremstillingen af et lægemiddel til behandling og hindring af overdreven fedme
DK0547952T3 (da) Anvendelse af modafinil til fremstilling af et antiisskæmisk lægemiddel
DE69435243D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
DE69332732T2 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
NO891896L (no) Fremgangsmaate og innretning for behandling av medisinsk spesialavfall.
DK140494A (da) Fremgangsmåde og anlæg til behandling af overgangszonemateriale
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DK91793D0 (da) Fremgangsmaade til overfladebehandling, midler til udoevelse og anvendelsen heraf
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE9305147U1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
DK0594528T3 (da) Fremgangsmåde og anlæg til behandling af halve slagtekroppe
DK0693912T3 (da) Apparat til medicinsk behandling
DE69418931T2 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DK0670721T3 (da) Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme
EA199900862A1 (ru) Способ лечения сосудистых нарушений
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DK0691957T3 (da) (S)-alfa-phenyl-2-pyridinethanamin-(S)-malat og dets anvendelse som et medikament.
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie